Cover storyContinued Process Verification In Pharma: What Literature Shows
CPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.
Cover storyCPV theory is well understood, but literature shows execution is uneven, here's what real-world data reveals about running Stage 3 well.

FibroBiologics patents 3D spheroid fibroblast wound therapy, raising GMP and process validation questions for cell therapy manufacturers.

AbbVie's etentamig met dual primary endpoints in Phase 3 CERVINO, signaling imminent GMP and fill-finish scale-up requirements for this BCMA bispecific.

Cellipont Bioservices reports its Texas facility has supported six cell therapy client programs expected to reach IND submission in 2026.

Eledon submits islet cell IND for tegoprubart and enrolls first patients across four transplant programs ahead of Phase 3 LEGACY trial.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
